



Establish the likelihood of amyloid pathology consistent with Alzheimer's disease



LifeLabs® ABeta 42/40 and p-tau217 Evaluation assesses beta-amyloid (Aβ) and phosphorylated tau (p-tau) to establish the likelihood of amyloid pathology consistent with Alzheimer's disease.



Insights can help patients **avoid invasive and less accessible testing** such as PET scans



The **AD-Detect Likelihood Score** is a composite interpretation created through a proprietary algorithm clinically validated utilizing a real-world cohort^{a,3}

The AD-Detect Likelihood Score

This panel combines Aβ42/40 and p-tau217 values into a single analytical interpretation, which has been shown to significantly improve predictive performance and accuracy for detecting amyloid positivity corresponding to the findings of an amyloid PET scan and establishing a diagnosis of Alzheimer's disease.

These determinations are intended to be used in combination with a full clinical evaluation, inclusive of the patient's clinical history and presentation, to completely assess the presence of Alzheimer's disease.

The release of the Alzheimer's Association's first clinical practice guideline provides evidence-based recommendations supporting the use of specific blood-based biomarker tests in the diagnostic assessment of suspected AD with specialized memory-care settings.⁴ LifeLabs offers a p-tau217 and Aβ42/40 evaluation panel with 91% sensitivity and specificity allowing you to triage, differentiate, or confirm Alzheimer's pathology.⁵

Rule in and rule out test

Patient with cognitive impairment presenting in specialized memory care setting

→ **Order LifeLabs ABeta 42/40 and p-tau217 Evaluation**

Panel components can be ordered separately. 10 day turnaround time.

Low likelihood:
< 0.3254

→ Amyloid PET positivity unlikely⁵ → Evaluate alternative causes

Indeterminate:
0.3254 – 0.6460

→ Consider amyloid PET, CSF test or repeat BBM in 1 year, depending on urgency⁶

High likelihood:
> 0.6460

→ Amyloid PET positivity likely⁵ → Diagnosis & treatment planning

Visit [LifeLabs.com/alzheimers-disease](https://www.lifelabs.com/alzheimers-disease) to learn more about our portfolio or [click here](#) to download requisition.

To receive the latest news and updates from LifeLabs, please join our email list by clicking the 'sign up' button.

Sign up

^a A well-characterized cohort from a National Institutes of Health (NIH) Alzheimer's Disease Research Center (ARDC).

References: 1. Weber D, Stroh M, et al. Development and clinical validation of a blood-based multi-biomarker algorithm for the evaluation of brain amyloid pathology. 2025, Peer-reviewed publication pending. | 2. Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology – Recommendations from the Global CEO Initiative on Alzheimer's disease. Nat Rev Neurol. 2024;20(7):426–439. doi:10.1038/s41582-024-00977-5 | 3. Data on file. Quest Diagnostics. AD-Detect Likelihood Score Validation, 2024. | 4. Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK, Okrahvi HR, Paczynski M, Schindler SE, Teunissen CE, Zetterberg H, Carrillo MC, Edelmayer RM, Mahinrad S, McAteer MB, Kahale LA, Pahlke S, Tampi MP. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025 Jul;21(7):e70535. doi:10.1002/alz.70535. PMID: 40729527; PMCID: PMC12306682. | 5. Weber DM, Stroh MA, Taylor SW, Lagier RJ, Louie JZ, Clarke NJ, Vaillancourt DE, Rayaprolu S, Duara R, Racke MK. Development and clinical validation of blood-based multi-biomarker models for the evaluation of brain amyloid pathology. medRxiv. 2025. doi:10.1101/2025.02.27.25322892. | 6. Schindler, S.E., Galasko, D., Pereira, A.C. et al. Acceptable performance of blood biomarker tests of amyloid pathology – recommendations from the Global CEO Initiative on Alzheimer's Disease. Nat Rev Neurol 20, 426–439 (2024). <https://doi.org/10.1038/s41582-024-00977-5>